Allergan Launched Online Resource Related to Voluntary Global Recall of BIOCELL®

| By | Allergan

Allergan plc has launched an online resource for patients, surgeons and healthcare professionals related to the voluntary global recall of BIOCELL®  textured breast implants and tissue expanders announced on July 24, 2019.

The easy-to-navigate website offers detailed information and specific guidance about the recent announcement, including the latest resources on the BIOCELL® withdrawal and warranty information.

“Patient safety is a priority for Allergan,”

said Charles Hugh-Jones MD, FRCP, Allergan’s Chief Medical Officer.

“We are committed to providing patients, surgeons and healthcare providers with the very latest information about the BIOCELL® withdrawal with this new site.”

Healthcare providers will find tools to help guide the identification of patients with BIOCELL®  textured devices, including a video resource and directions how to find patient information, and instructions how to return unused BIOCELL® implants.

Allergan voluntarily withdrew BIOCELL® implants as a precaution following notification of recently updated global safety information concerning the uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) provided by the Food & Drug Administration (FDA).

Importantly, the FDA and other health authorities have not recommended the removal or replacement of textured breast implants or tissue expanders in asymptomatic patients.

Patients are advised to speak with a board-certified plastic surgeon about the risks and benefits of their implant type and address any concerns they may have.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.